<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101462</url>
  </required_header>
  <id_info>
    <org_study_id>16354</org_study_id>
    <nct_id>NCT03101462</nct_id>
  </id_info>
  <brief_title>Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years</brief_title>
  <official_title>A Randomized, Open-Label, Study to Evaluate the Immunogenicity of One Dose of Live Attenuated Influenza Vaccine (LAIV) Compared to One Dose of Trivalent Inactivated Influenza Vaccine (IIV) in Adults 18-49 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, open-label, single-site study at Saint Louis University will enroll
      approximately 40 subjects who are healthy, 18 to 49 years old. Subjects will be randomized in
      a 1:1 fashion to receive either licensed trivalent FluMist containing (2010-2011 season
      appropriate), or licensed inactivated trivalent influenza vaccine (2010-2011 season
      appropriate) so that approximately 20 subjects will be randomized to receive LAIV, and 20
      will receive IIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase IV, randomized, open-label, single-site study at Saint Louis University will
      enroll approximately 40 subjects who are healthy, 18 to 49 years old. Subjects will be
      randomized in a 1:1 fashion to receive either licensed inactivated influenza vaccine (IIV)
      (2010-2011 season appropriate) or licensed live attenuated influenza vaccine (LAIV)
      (2010-2011 season appropriate) so that approximately 20 subjects will be randomized to
      receive IIV, and 20 will receive LAIV. Subjects will receive 1 dose of IIV or LAIV in the
      Center for Vaccine Development on Day 0 and will return to the site on days 7 and 45 to
      assess immunogenicity. Subjects will be asked to report any serious adverse events. Blood
      samples and nasal washes for assessment of immune responses will be obtained at three time
      points: on Day 0 prior to dosing with IIV or LAIV, and at visits conducted 7 and 45-51 days
      post vaccination. The study will be conducted just prior to and during the influenza season.
      Subjects will receive a single dose of IIV or LAIV administered as instructed per package
      insert. Two contacts will be made with subjects, either telephone calls or e-mail, to collect
      serious adverse events only, one at Days 28-35, and one at approximately Days 180-190 to
      conclude the subject's participation. The duration of each subject's participation is
      approximately 6 months. The primary immune studies conducted with collected samples will
      include serum hemagglutinin inhibition (HAI) antibody titers, nasal wash influenza-specific
      secretory immunoglobulin A (IgA) responses, peripheral blood interferon gamma (IFN-Î³) ELISPOT
      assays and peripheral blood carboxyfluorescein succinimidyl ester (CFSE)
      dilution/intracellular cytokine staining flow cytometric assays. In addition, frozen serum
      and peripheral blood mononuclear cells (PBMC) samples will be used in exploratory assays to
      determine the kinetics and nature of innate responses and the detailed molecular signatures
      of memory T cells induced by IIV and LAIV vaccinations. Investigators will be performing
      genome-wide expression studies, but will not perform DNA sequencing and will not send
      anything other than coded samples outside of Saint Louis University.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2011</start_date>
  <completion_date type="Actual">November 9, 2011</completion_date>
  <primary_completion_date type="Actual">May 13, 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to one of two different groups to receive either licensed inactivated influenza vaccine (IIV) or licensed live attenuated influenza vaccine (LAIV) from the 2010-2011 season.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Antibody Responses</measure>
    <time_frame>Day 0, Day 7, and Day 45</time_frame>
    <description>Geometric mean hemagglutination inhibition titers to three different influenza viruses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T-cell Responses</measure>
    <time_frame>Day 0, Day 7, and Day 45</time_frame>
    <description>Number of Interferon gamma ELISPOT spot forming cells (SFC) per million Peripheral Blood Mononuclear Cells (PBMCs) were calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cluster of Differentiation 4 (CD4+) T Cells That Proliferate and Produce Interferon (IFN)-Gamma After Antigen Activation</measure>
    <time_frame>Day 0, Day 7, and Day 45</time_frame>
    <description>Mean absolute numbers of CD4(+), Carboxyfluorescein succinimidyl ester [CFSE(low)] IFN-gamma(+), and T cells after activation with a specific antigen measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secretory Immunoglobulin A (IgA) Responses</measure>
    <time_frame>Day 0 and Day 45</time_frame>
    <description>Influenza virus strain-specific nasal wash secretory immunoglobulin A (IgA) titers by ELISA was measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemagglutinin Immunoglobulin A (IgA) Responses</measure>
    <time_frame>Day 7</time_frame>
    <description>Hemagglutinin (HA) specific nasal wash secretory immunoglobulin A (IgA) of serum reactivity with HA bound to ELISA plates.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One dose of 0.5 mL Licensed Inactivated Influenza Vaccine (IIV) on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One dose of 0.5 mL Licensed Live Attenuated Influenza Vaccine (LAIV) on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Influenza Vaccine</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>IIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live Attenuated Influenza Vaccine</intervention_name>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>LAIV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age 18 to 49 years, inclusive, on the day of randomization (reached his
             or her 18th year birthday but not yet reached his or her 50th year birthday) at the
             time of the dose of study product

          -  Written informed consent and a locally required authorization (eg, HIPAA in the USA, )
             obtained from the subject prior to performing any protocol-related procedures.

          -  Females of child-bearing potential, (ie, unless surgically sterile [eg, bilateral
             tubal ligation, bilateral oophorectomy, or hysterectomy], has sterile male partner, is
             at least 1 year post-menopausal, or practices abstinence) must use an effective method
             of avoiding pregnancy (including oral, transdermal, or implanted contraceptives,
             intrauterine device, female condom with spermicide, diaphragm with spermicide,
             cervical cap, or use of a condom with spermicide by the sexual partner) for 30 days
             prior to the first dose of study product, and must agree to continue using such
             precautions for 60 days after the dose of vaccine due to a potential dose of live
             vaccine product. In addition, the subject must also have a negative urine or blood
             pregnancy test at screening and, if screening and Day 0 do not occur on the same day,
             a negative urine pregnancy test on the day of vaccination prior to randomization.
             Investigator judgment is required to assess a female subject's capability of
             pregnancy.

          -  Are in good health, as determined by vital signs, medical history to ensure any
             existing medical diagnoses or conditions are stable and not considered clinically
             significant by physician investigator, and targeted physical examination based on
             medical history.

          -  Able to complete follow-up period of 180 days post dose of vaccine as required by the
             protocol

          -  Subject available by telephone

          -  Able to understand and comply with the requirements of the protocol, as judged by the
             investigator

        Exclusion Criteria:

        Any of the following would exclude the subject from participation in the study:

          -  Have an acute illness, including an oral temperature â¥ 100.4Â°F, within 3 days prior to
             vaccination.

          -  Participated in an investigational influenza vaccine study or had a known infection
             with &quot;flu&quot; since 2007 (confirmed by laboratory culture, including subtype of the
             influenza A virus (H1N1) investigational vaccines or illness).

          -  Previous vaccination against influenza in 2007, 2008, 2009 or 2010 with seasonal
             trivalent live or inactivated influenza vaccine (including H1N1 vaccines).

          -  Current or expected receipt of immunosuppressive medications (inhaled and topical
             corticosteroids are permitted) including corticosteroids (â¥ 20 mg/day of prednisone
             equivalent given daily or on alternate days for â¥ 14 days) within a 30 day window
             around dose of study vaccine product Note: topical corticosteroids for uncomplicated
             dermatitis may be used throughout the study according to the judgment of the
             investigator; topical calcineurin inhibitors may be used in accordance with their
             package insert at entry and during study participation.

          -  Receipt of immunoglobulin or blood products within 90 days before randomization into
             the study or expected receipt during study participation

          -  Received an experimental agent within 1 month prior to vaccination in this study or
             expect to receive an experimental agent during the active study period (prior to Day
             60 after vaccination (Experimental agent includes: vaccine, biologic, device, or
             medication).

          -  Have received any live licensed vaccines within 4 weeks or inactivated licensed
             vaccines within 2 weeks prior to vaccination in this study or plan receipt of such
             vaccines within 60 days following the vaccination.

          -  Any known immunosuppressive condition or immune deficiency disease including known
             cancer illness or organ transplant

          -  Have known active HIV, Hepatitis B or Hepatitis C infection.

          -  Have a known allergy to eggs or other components of the vaccine (including gelatin,
             formaldehyde, octoxinol, thimerosal, gentamycin and chicken protein) or severe
             reactions to previous influenza vaccinations.

          -  History of Guillain-BarrÃ© syndrome

          -  Use of antiviral agents with activity against influenza virus (including amantadine,
             rimantadine, oseltamivir and zanamivir) within 30 days prior to dose of study vaccine
             products or anticipated use within 30 days after vaccination

          -  Breastfeeding woman

          -  History of alcohol or drug abuse that, in the opinion of the investigator, would
             affect the subject's safety or compliance with study

          -  Previous medical history, evidence of an intercurrent illness or any condition that,
             in the opinion of the investigator, would interfere with evaluation of the study
             vaccine products or interpretation of subject safety or that may compromise the safety
             of the subject in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel F Hoft, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <reference>
    <citation>Hoft DF, Lottenbach KR, Blazevic A, Turan A, Blevins TP, Pacatte TP, Yu Y, Mitchell MC, Hoft SG, Belshe RB. Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults. Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00414-16. doi: 10.1128/CVI.00414-16. Print 2017 Jan.</citation>
    <PMID>27847366</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <results_first_submitted>June 19, 2017</results_first_submitted>
  <results_first_submitted_qc>November 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2019</results_first_posted>
  <last_update_submitted>November 6, 2018</last_update_submitted>
  <last_update_submitted_qc>November 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Louis University</investigator_affiliation>
    <investigator_full_name>Daniel Hoft, MD, PhD</investigator_full_name>
    <investigator_title>Director, Division of Infectious Diseases, Allergy &amp; Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Inactivated Influenza Vaccine (IIV)</title>
          <description>Subjects aged 18-49 years received one dose of Inactivated Influenza Vaccine (IIV) intramuscularly.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 Live Attenuated Influenza Vaccine (LAIV)</title>
          <description>Subjects 18-49 years of age received one dose of Live Attenuated Influenza Vaccine (LAIV) intranasally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missed Visit 02 and/or Visit 03</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In the IIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.
In the LAIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.</population>
      <group_list>
        <group group_id="B1">
          <title>Inactivated Influenza Vaccine (IIV)</title>
          <description>Eighteen subjects received one dose 0.5 mL of Inactivated Influenza Vaccine intramuscularly on Day 0.</description>
        </group>
        <group group_id="B2">
          <title>Live Attenuated Influenza Vaccine (IIV)</title>
          <description>Eighteen subjects received one dose 0.5 mL Live Attenuated Influenza Vaccine intranasally on Day 0.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="10.8"/>
                    <measurement group_id="B2" value="30.4" spread="9.8"/>
                    <measurement group_id="B3" value="31.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Antibody Responses</title>
        <description>Geometric mean hemagglutination inhibition titers to three different influenza viruses</description>
        <time_frame>Day 0, Day 7, and Day 45</time_frame>
        <population>For IIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.
For LAIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>One 0.5 mL dose of IIV given intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Live Attenuated Influenza Vaccine (LAIV)</title>
            <description>One 0.5 mL dose of LAIV given intranasally.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Antibody Responses</title>
          <description>Geometric mean hemagglutination inhibition titers to three different influenza viruses</description>
          <population>For IIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.
For LAIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A virus subtype H1N1 (A/H1N1) Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.76" lower_limit="6.2" upper_limit="22.4"/>
                    <measurement group_id="O2" value="11.11" lower_limit="6.3" upper_limit="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.03" lower_limit="24.3" upper_limit="91.1"/>
                    <measurement group_id="O2" value="9.33" lower_limit="5.4" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.59" lower_limit="51.6" upper_limit="200"/>
                    <measurement group_id="O2" value="12.70" lower_limit="7.0" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A virus subtype H3N2 (A/H3N2) Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" lower_limit="4.1" upper_limit="9.9"/>
                    <measurement group_id="O2" value="7.44" lower_limit="4.6" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.96" lower_limit="10.5" upper_limit="30.8"/>
                    <measurement group_id="O2" value="7.13" lower_limit="4.1" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.00" lower_limit="17.5" upper_limit="58.4"/>
                    <measurement group_id="O2" value="9.70" lower_limit="5.9" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.41" lower_limit="5.2" upper_limit="10.6"/>
                    <measurement group_id="O2" value="10.71" lower_limit="6.6" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.77" lower_limit="14.2" upper_limit="33.4"/>
                    <measurement group_id="O2" value="11.31" lower_limit="6.8" upper_limit="18.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.32" lower_limit="24.4" upper_limit="66.7"/>
                    <measurement group_id="O2" value="12.70" lower_limit="7.9" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/H1N1 Day 0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>ANOVA</non_inferiority_desc>
            <p_value>0.89</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/H1N1 Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.00082</p_value>
            <p_value_desc>This is the calculated p-value.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/H1N1 Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.000076</p_value>
            <p_value_desc>This is the calculated p-value</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/H3N2 Day 0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/H3N2 Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0186</p_value>
            <p_value_desc>This is the calculated p-value</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A/H3N2 Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0052</p_value>
            <p_value_desc>This is the calculated p-value</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Influenza B Day 0</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Influenza B Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.061</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Influenza B Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T-cell Responses</title>
        <description>Number of Interferon gamma ELISPOT spot forming cells (SFC) per million Peripheral Blood Mononuclear Cells (PBMCs) were calculated.</description>
        <time_frame>Day 0, Day 7, and Day 45</time_frame>
        <population>For IIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.
For LAIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>One 0.5 mL dose of IIV given intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Live Attenuated Influenza Vaccine (LAIV)</title>
            <description>One 0.5 mL dose of LAIV given intranasally.</description>
          </group>
        </group_list>
        <measure>
          <title>T-cell Responses</title>
          <description>Number of Interferon gamma ELISPOT spot forming cells (SFC) per million Peripheral Blood Mononuclear Cells (PBMCs) were calculated.</description>
          <population>For IIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.
For LAIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.</population>
          <units>Cells/Million PBMC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medium Alone Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.51"/>
                    <measurement group_id="O2" value="2.51" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium Alone Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" spread="4.21"/>
                    <measurement group_id="O2" value="1.05" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium Alone Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.31"/>
                    <measurement group_id="O2" value="2.35" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peptide Pool 1 + Peptide Pool 2 Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.55" spread="23.12"/>
                    <measurement group_id="O2" value="61.52" spread="17.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peptide Pool 1 + Peptide Pool 2 Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.76" spread="26.98"/>
                    <measurement group_id="O2" value="81.11" spread="14.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peptide Pool 1 + Peptide Pool 2 Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.94" spread="19.03"/>
                    <measurement group_id="O2" value="65.55" spread="15.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live H3N2 Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.90" spread="29.93"/>
                    <measurement group_id="O2" value="126.20" spread="28.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live H3N2 Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.79" spread="60.12"/>
                    <measurement group_id="O2" value="254.26" spread="49.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live H3N2 Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.99" spread="35.49"/>
                    <measurement group_id="O2" value="146.99" spread="19.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FluMist Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.26" spread="12.61"/>
                    <measurement group_id="O2" value="43.16" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FluMist Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.25" spread="24.83"/>
                    <measurement group_id="O2" value="104.81" spread="43.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Mist Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.00" spread="21.07"/>
                    <measurement group_id="O2" value="49.48" spread="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 and 2, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 and 2, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Live H3N2, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Live H3N2, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Flumist, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Flumist, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 and 2, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 and 2, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Live H3N2, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Live H3N2, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Flumist, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Flumist, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cluster of Differentiation 4 (CD4+) T Cells That Proliferate and Produce Interferon (IFN)-Gamma After Antigen Activation</title>
        <description>Mean absolute numbers of CD4(+), Carboxyfluorescein succinimidyl ester [CFSE(low)] IFN-gamma(+), and T cells after activation with a specific antigen measured by flow cytometry</description>
        <time_frame>Day 0, Day 7, and Day 45</time_frame>
        <population>For IIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.
For LAIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>One 0.5 mL dose of IIV given intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Live Attenuated Influenza Vaccine (LAIV)</title>
            <description>One 0.5 mL dose of LAIV given intranasally.</description>
          </group>
        </group_list>
        <measure>
          <title>Cluster of Differentiation 4 (CD4+) T Cells That Proliferate and Produce Interferon (IFN)-Gamma After Antigen Activation</title>
          <description>Mean absolute numbers of CD4(+), Carboxyfluorescein succinimidyl ester [CFSE(low)] IFN-gamma(+), and T cells after activation with a specific antigen measured by flow cytometry</description>
          <population>For IIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.
For LAIV group, 18 subjects completed Visit 02 and 18 subjects completed Visit 03.</population>
          <units>T Cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medium Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.79" spread="38.19"/>
                    <measurement group_id="O2" value="83.80" spread="20.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1075.24" spread="711.71"/>
                    <measurement group_id="O2" value="65.45" spread="18.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.86" spread="224.16"/>
                    <measurement group_id="O2" value="144.58" spread="64.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live H3N2 Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15939.07" spread="5984.03"/>
                    <measurement group_id="O2" value="22958.77" spread="8371.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live H3N2 Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32527.86" spread="11165.21"/>
                    <measurement group_id="O2" value="28557.23" spread="8835.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live H3N2 Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21320.85" spread="6054.77"/>
                    <measurement group_id="O2" value="15654.57" spread="4626.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FluMist Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14009.94" spread="6259.10"/>
                    <measurement group_id="O2" value="12552.22" spread="3718.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Mist Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26999.98" spread="9510.82"/>
                    <measurement group_id="O2" value="24265.06" spread="5147.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Mist Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21704.19" spread="6455.24"/>
                    <measurement group_id="O2" value="14618.15" spread="4314.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 and Peptide Pool 2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 and Peptide Pool 2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Live H3N2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Live H3N2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Flumist CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Flumist CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 and Peptide Pool 2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Peptide Pool 1 and Peptide Pool 2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Live H3N2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Live H3N2 CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Flumist CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Flumist CD4+/CFSE(low)/IFN-gamma+, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Secretory Immunoglobulin A (IgA) Responses</title>
        <description>Influenza virus strain-specific nasal wash secretory immunoglobulin A (IgA) titers by ELISA was measured</description>
        <time_frame>Day 0 and Day 45</time_frame>
        <population>For IIV group, 18 subjects completed Visit 03. For LAIV group, 18 subjects completed Visit 03.</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>One 0.5 mL dose of IIV given intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Live Attenuated Influenza Vaccine (LAIV)</title>
            <description>One 0.5 mL dose of LAIV given intranasally.</description>
          </group>
        </group_list>
        <measure>
          <title>Secretory Immunoglobulin A (IgA) Responses</title>
          <description>Influenza virus strain-specific nasal wash secretory immunoglobulin A (IgA) titers by ELISA was measured</description>
          <population>For IIV group, 18 subjects completed Visit 03. For LAIV group, 18 subjects completed Visit 03.</population>
          <units>Titers</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza A/H1N1 Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="1.25" upper_limit="64"/>
                    <measurement group_id="O2" value="16.25" lower_limit="3" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A/H1N1 Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.75" lower_limit="1.25" upper_limit="2328"/>
                    <measurement group_id="O2" value="28.5" lower_limit="4" upper_limit="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A/H3N2 Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="5" upper_limit="69"/>
                    <measurement group_id="O2" value="32.25" lower_limit="1.25" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza A/H3N2 Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" lower_limit="3" upper_limit="476"/>
                    <measurement group_id="O2" value="57.25" lower_limit="10" upper_limit="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="3" upper_limit="50"/>
                    <measurement group_id="O2" value="9.75" lower_limit="3" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza B Day 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="1.25" upper_limit="77"/>
                    <measurement group_id="O2" value="16.75" lower_limit="5" upper_limit="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Influenza A/H1N1 HA, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Influenza A/H3N2 HA, Day 0 and 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Influenza B HA, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Influenza A/H1N1 HA, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Influenza A/H3N2 HA, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Influenza B HA, Day 0 and Day 45</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemagglutinin Immunoglobulin A (IgA) Responses</title>
        <description>Hemagglutinin (HA) specific nasal wash secretory immunoglobulin A (IgA) of serum reactivity with HA bound to ELISA plates.</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>One 0.5 mL dose of IIV given intramuscularly.</description>
          </group>
          <group group_id="O2">
            <title>Live Attenuated Influenza Vaccine (LAIV)</title>
            <description>One 0.5 mL dose of LAIV given intranasally.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutinin Immunoglobulin A (IgA) Responses</title>
          <description>Hemagglutinin (HA) specific nasal wash secretory immunoglobulin A (IgA) of serum reactivity with HA bound to ELISA plates.</description>
          <units>Fold change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA anti-H1N1 HA Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="0.40"/>
                    <measurement group_id="O2" value="8.42" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA anti-H3N2 Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.24"/>
                    <measurement group_id="O2" value="9.42" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA anti-Influenza B Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.58"/>
                    <measurement group_id="O2" value="9.55" spread="4.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fold increase IgA anti-H1N1 HA, Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fold increase IgA anti-H3N2, Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fold increase IgA anti-influenza B HA, Day 7</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from Day 0 through Day 28. Serious Adverse Events were collected from Day 0 through Day 180.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1 Licensed Trivalent FluMist</title>
          <description>Subjects received one dose of Licensed Trivalent FluMist at Day 0.</description>
        </group>
        <group group_id="E2">
          <title>Group 1 Inactvated Trivalent Influenza Vaccine</title>
          <description>Subjects received one dose of Inactivated Trivalent Influenza Vaccine at Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel F. Hoft, MD, PhD</name_or_title>
      <organization>Saint Louis University</organization>
      <phone>314-977-5500</phone>
      <email>daniel.hoft@health.slu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

